Study: Tamoxifen cuts breast cancer return risk long-term

02/20/2007 | BBC

An international study concludes the hormone drug tamoxifen continues to reduce a woman's risk of breast cancer recurrence for several years after she stops taking the drug. The course of taking tamoxifen to block the effect of the estrogen hormone normally is five years, but the study said the risk reduction lasted at least as long as eight years.

View Full Article in:

BBC

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN